Predictive Oncology Inc. POAI Archives - Page 16 of 19

FridayJan 10, 2020 1:08 pm

Predictive Oncology Inc. (NASDAQ: POAI) Working to Create World’s First Comprehensive, Actionable Multi-Omic Data Set for Ovarian Cancer

POAI plans to have first predictive model of ovarian cancer ready for initial commercialization in Q1 2020 First batch of 400 ovarian cancer subjects in initiative has been sequenced Groundbreaking AI-driven model of ovarian cancer will be capable of predicting tumor drug response, patient outcome Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has updated the commercialization of its pioneering CancerQuest 2020 initiative (http://ibn.fm/gs5Qh). Based on the updated announcement, the company plans on having its first predictive model of ovarian cancer ready for initial commercialization in revenue-generating projects with Pharma in…

MondayJan 06, 2020 1:05 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Appointment of Pam Prior to its Board of Directors

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the unanimous appointment of Pam Prior, CPA, to its Board of Directors. According to the update, Prior is the founder and CEO of Priorities Group, Inc., a provider of CFO services to small and mid-sized businesses, and has approximately 35 years of previous experience in accounting, predominantly in management as a chief financial officer and controller. “Predictive Oncology is very fortunate to announce that Pam Prior is joining our Board…

MondayDec 30, 2019 2:06 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building AI-driven Ovarian Cancer Model to Predict Tumor Drug Response, Patient Outcome

Predictive Oncology (NASDAQ: POAI), through its subsidiary Helomics, is sequencing ovarian cancers as part of a CancerQuest 2020 project, building the largest ovarian multi-omic database in the world. An article discussing the company reads, “As part of its CancerQuest 2020 project, Predictive Oncology, through Helomics, recently signed a collaborative agreement with UPMC-Magee to establish a data- and artificial-intelligence-driven approach to treating ovarian cancer. Based on the agreement, the partnership is designed to validate the significant value of using AI-powered decision-making for identifying specific treatments on specific genotypes to predict clinical outcomes for ovarian cancer patients. . . . Helomics has…

ThursdayDec 26, 2019 12:56 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s Revolutionary Technology Enables Faster, More Accurate Tumor Identification

Data and artificial-intelligence (“AI”) driven, discovery-services company Predictive Oncology’s (NASDAQ: POAI) subsidiary TumorGenesis is developing quicker, less costly and more precise Patient Derived Xenograft (“PDx”) cancer models that better mimic the patient’s tumor. An article discussing the company reads, “TumorGenesis excels not only in identifying cancer cell lines but also in developing a medium necessary to grow cancer-cell colonies in a way that will not compromise their integrity — a consideration critical to the success of every cancer research. This revolutionary technology is creating an unparalleled competitive advantage for the parent company POAI, as it allows for faster and more…

TuesdayDec 17, 2019 10:04 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Extension of Secured Promissory Note

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the extension of its secured promissory note. According to the update, the note’s maturity date was extended from December 31, 2019 to March 31, 2020. In addition, the outstanding principal amount of the note was increased by $120,000 to a current principal amount of $2,029,104. Predictive Oncology issued 15,000 shares of common stock to the investor in connection with certain amended terms. To view the full press release, visit http://ibn.fm/zyi8m…

MondayDec 16, 2019 11:31 am

Predictive Oncology Inc. (NASDAQ: POAI) Notes Indications of Interest in Medical Division; Regains Nasdaq Price Compliance

Several parties have indicated interest in potential acquisition of POAI’s Skyline Medical division The division has seen recent success with growing sales of its patented, FDA-approved STREAMWAY System POAI also regained compliance with Nasdaq’s minimum bid price requirement Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has revealed that several parties have indicated interest in the potential acquisition of Skyline Medical, the division of the company that produces and sells the STREAMWAY System (http://ibn.fm/fjuZr). The patented, FDA-approved STREAMWAY System is the first truly continuous, direct-to-drain fluid disposal system designed specifically for…

FridayDec 13, 2019 11:45 am

Predictive Oncology Inc. (NASDAQ: POAI) Reports 58% Revenue Increase; Notes Business Highlights for Q3 2019

POAI sees Q3 2019 revenue total $522,696 from $329,930 in Q3 2018 Company reports records sales of proprietary systems, supplies Significant business highlights indicate continued momentum as Predictive Oncology looks to bright future Predictive Oncology Inc. (NASDAQ: POAI), an artificial intelligence (AI) and data-driven functional precision medicine company, released its financial results for Q3 2019, and the numbers are impressive, including quarter revenues increasing 58% year over year (http://ibn.fm/TmZoV). The company also provided a business update outlining significant highlights reached during the quarter. POAI reported that revenue for the quarter ended September 30, 2019, totaled $522,696, compared with $329,930 for the same period of…

ThursdayDec 12, 2019 11:52 am

Predictive Oncology Inc. (NASDAQ: POAI) Key Player in AI Implementation in Ovarian Cancer Detection

POAI subsidiary sequencing ovarian cancers as part of CancerQuest 2020 project, building largest ovarian multi-omic database in the world Company’s work designed to speed development of new drugs, provide therapeutic choices Helomics recently signed collaborative agreement with UPMC-Magee to establish data- and artificial-intelligence-driven approach to treating ovarian cancer The power of artificial intelligence (AI) to assist in the detection of ovarian cancer much earlier than previously possible is being recognized worldwide. A company in the United Kingdom is touting the ability of AI to eliminate late detection of ovarian cancer, thanks to advancements in health-care technology (http://ibn.fm/AOmHt). The contribution AI is…

MondayDec 09, 2019 12:10 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Updates on Commercialization of Cancer Quest 2020 Initiative

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced updates on the commercialization of its CancerQuest 2020 initiative. According to the update, the Company is confident that its first predictive model of ovarian cancer will be ready for initial commercialization in revenue generating projects with Pharma in the first quarter of 2020. Predictive Oncology’s Helomics division has been working closely with its sequencing partner to optimize and scale the generation of both genomic and transcriptomic data and has sequenced…

ThursdayDec 05, 2019 1:52 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Tech Primed to Play Key Role in Cancer Drug Development Efforts

Predictive Oncology subsidiary TumorGenesis developing faster, less costly, and more accurate PDx cancer models that better mimic the patient's tumor TumorGenesis revolutionary technology will provide pharmaceuticals with quicker and more effective drug development while significantly improving patient outcomes There’s an unmet need for a multi-omic approach (genome, transcriptome, epigenome, proteome, responseome, and microbiome), but such data is difficult to generate quickly. Predictive Oncology has access to historical data that competitors need at least five years to develop, which presents a multi-million-dollar market opportunity The global cancer diagnostics market was valued at $144.4 billion in 2018 and is expected to grow…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI